Spinal cord tumor in a patient with multiple sclerosis: case report

Taricco, Mario Augusto; Machado, André G.; Callegaro, Dagoberto; Marino, Raul

doi:10.1590/s0004-282x2002000300025

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Como já mencionado, o SNC pode ser lesionado traumaticamente de várias maneiras produzindo vários padrões de sintomas. Além disso, esse tecido pode ser comprometido através de infecções, por alterações genéticas ocasionando mal formação, como a espinha bífida, ou afetada por doenças neurodegenerativas como a esclerose múltipla, uma doença desmielinizante 24,25 .…”

Section: Desenvolvimentounclassified

Tratamento farmacológico e regeneração do Sistema Nervoso Central em situações traumáticas

Gúzen

Figueirêdo²,

Guzen

et al. 2019

Rev Neurocienc

View full text Add to dashboard Cite

Evidências recentes mostram a influência do meio no crescimento de fibras nervosas lesadas no Sistema Nervoso Central (SNC), assim como o potencial do tratamento farmacológico em tornar esse meio mais propício à regeneração de neurônios centrais. Axônios de neurônios do sistema nervoso periférico (SNP) regeneram prontamente no interior de nervos lesados quando os cotos destes são adequadamente posicionados. Esta capacidade se deve a propriedades intrínsecas dos neurônios periféricos, bem como ao meio permissivo para o crescimento das fibras nervosas no interior do nervo lesado. O ambiente de lesão dos axônios do SNC difere muito daquele do SNP. Ao contrário dos nervos, os axônios do SNC não são estruturalmente separados por bainhas perineurais e neurilemais, estruturas que fornecem um substrato anatômico para o crescimento da fibra lesada. Deste modo, a terapia farmacológica é capaz de exercer suas funções no SNC, tanto que, hoje em dia, são permitidas injeções de células após cultivo e administração de fármacos após determinada lesão aguda no SNC.

show abstract

Section: Desenvolvimentounclassified

Tratamento farmacológico e regeneração do Sistema Nervoso Central em situações traumáticas

Gúzen

Figueirêdo²,

Guzen

et al. 2019

Rev Neurocienc

View full text Add to dashboard Cite

show abstract

“…Another large study investigated the occurrence of brain tumors in 33 different autoimmune diseases and found that none of them (including MS) influences the risk of glioma development but that autoimmune diseases negatively affect survival in glioma and meningioma patients, probably due to the added physical burden or therapeutic limitations [3]. Accordingly, some of the challenges the clinical management of concurrent CNS tumors and MS pose have been described in the literature but due to the rare coincidence of these two CNS diseases, current evidence is limited to single case reports and, to our best knowledge, no cohort studies have been reported [4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

et al. 2022

View full text Add to dashboard Cite

Introduction The concurrent presence of both central nervous system (CNS) tumors and multiple sclerosis (MS) poses various diagnostic and therapeutic pitfalls and makes the clinical management of such patients challenging. Methods In this retrospective, single-center cohort study, we searched our clinical databases (2006–2019) for patients with concurrent CNS tumors and MS and described their disease courses. Age at diagnosis of the respective disease and probabilities for MS disease activity events (DAEs) with vs. without prior tumor-specific therapy were tested pairwise using t-test for dependent samples and exact binomial test. Results N = 16 patients with concurrent CNS tumors and MS were identified. MS diagnosis preceded the CNS oncological diagnosis by an average of 9 years (p = 0.004). More DAEs occurred in patients without prior chemotherapy (83.3%) than in patients with prior chemotherapy (16.7%; p = 0.008). This effect did not reach significance for patients with prior radiation therapy/radiosurgery (66.7% vs. 33.3%, p = 0.238). The average interval between DAEs and the last documented lymphopenia was 32.25 weeks. Conclusions This study describes the clinical and demographic features of patients with concurrent CNS tumors and MS and suggests several practical approaches to their clinical management. Our findings suggest that adding a disease-modifying MS therapy to the regimen of patients treated with chemotherapy is necessary only if the patient suffers from a highly active, aggressive course of MS. In view of the lack of prospective trials, individual risk assessments should remain the foundation of the decision on MS treatment in concurrent CNS tumor diseases.

show abstract

Genetic characterization of gliomas arising in patients with multiple sclerosis

et al. 2012

View full text Add to dashboard Cite

The co-occurrence of gliomas and multiple sclerosis (MS) in the same patient is uncommon, but a well-reported phenomenon. Most have been high grade astrocytic tumors that developed after the diagnosis of MS, leading authors to postulate that chronic gliosis in demyelinative plaques might be the underlying substrate for secondary induction of a glial neoplasm. Until recently, however, genetic tools have not been available to test the hypothesis that high grade gliomas might arise from longstanding chronic gliosis, with transformation to low grade glioma, and eventually GBM, i.e., be secondary GBMs. We searched our surgical neuropathology and MS Brain Bank databases over the past 25 years (1987-2011) and identified eight cases of co-occurring MS and glioma. After careful review to guarantee both diagnoses, cases were studied by fluorescence in situ hybridization for genetic markers appropriate to diagnosis, as well as by direct sequencing for IDH1/2 and P53. No unusual genetic features were detected in our cohort; further, the 4 GBMs we did identify did not have clinical features of secondary glioblastomas nor did any of the four manifest IDH-1 immunohistochemical expression or IDH1/2 mutations, as might be expected in secondary GBMs. Conversely, PTEN loss and EGFR expression, features often found in primary GBMs, but seldom identified in secondary GBMs, were found in 3 of 4 GBMs. We conclude that gliomas in MS patients have genetic features paralleling counterparts in non-MS patients. There is no strong genetic evidence for GBMs to be secondary GBMs.

show abstract

Spinal cord tumor in a patient with multiple sclerosis: case report

Cited by 7 publications

References 5 publications

Tratamento farmacológico e regeneração do Sistema Nervoso Central em situações traumáticas

Tratamento farmacológico e regeneração do Sistema Nervoso Central em situações traumáticas

Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management

Genetic characterization of gliomas arising in patients with multiple sclerosis

Contact Info

Product

Resources

About